基于正常组织约束的高剂量放疗联合同步化疗治疗不可切除III期非小细胞肺癌
本研究回顾性分析140例不可切除III期非小细胞肺癌患者,根据正常组织约束个体化处方放疗剂量,≥66 Gy为高剂量组(71例),<66 Gy为标准剂量组(69例)。高剂量组中位生存期33.5个月显著高于标准剂量组21个月(p<0.0001),5年总生存率37.8%对16.7%,两组严重毒性无差异。
要点
- 基于正常组织约束的个体化等毒性剂量提升至≥66 Gy可行。
- 高剂量组中位生存期33.5个月,标准剂量组21个月(p<0.0001)。
- 高剂量组5年总生存率37.8%,标准剂量组16.7%。
核心结论
- 处方剂量与生存的正相关提示基于正常组织约束的个体化等毒性剂量提升可能改善III期非小细胞肺癌生存。
研究设计与样本
- 回顾性研究,2006年3月至2012年9月纳入140例不可切除III期非小细胞肺癌患者。
- 根据正常组织约束计算个体化处方剂量,≥66 Gy为高剂量组(71例),<66 Gy为标准剂量组(69例)。
- 主要终点为总生存期,采用调强放疗优化靶区并减少危及器官受量。
主要发现
- 高剂量组中位生存期33.5个月,标准剂量组21个月(p<0.0001)。
- 高剂量组5年总生存率37.8%,标准剂量组16.7%。
- 高剂量组中位无进展生存期19个月,标准剂量组11个月(p<0.0001)。
- 两组严重(3-5级)毒性反应无差异。
关键数值与推荐
- 高剂量组定义为总肿瘤放疗剂量≥66 Gy,标准剂量组为<66 Gy。
- 分期采用美国癌症联合委员会第八版。
临床怎么用
- 对不可切除III期非小细胞肺癌,可在正常组织约束下个体化提升放疗剂量至≥66 Gy并联合同步化疗。
- 需注意该结论来自回顾性研究,剂量提升策略应在临床实践中谨慎评估。
局限性
- 回顾性研究设计,样本量有限(140例),可能存在选择偏倚。
- 单中心数据,来自中国患者队列,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We aimed to investigate the potential of individual isotoxic dose escalation based on normal tissue constraints (NTC), hypothesizing that high dose radiation therapy would be superior to standard-dose in concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Individually prescribed radiation doses were calculated based on NTC. Patients with total tumour radiation doses ≥66 Gy were assigned to the high dose (HD, ≥66 Gy) group, and all other patients were assigned to the standard-dose (SD, <66 Gy) group. Each patient was retrospectively assigned an Eighth edition of American Joint Committee on Cancer disease stage based on the imaging data of initial diagnosis to avoid over- and under-staging. Intensity modulated radiation therapy plans were optimized to minimize the volumes of organs at risk exposed to radiation. The primary endpoint was overall survival. RESULTS: From March 2006 to September 2012, 140 patients were enrolled and assigned to two groups: 71 patients into the HD group and 69 patients into the SD group. The median survival time (MST) was significantly higher in the HD group (33.5 months) than in the SD group (21 months), (p < 0.0001). Overall 5-year survival rates were significantly higher in the HD group than in the SD group (37.8% vs 16.7%). Median progression-free survival was 19 months in the HD group and 11 months in the SD group (p < 0.0001). No difference in severe (grade 3-5) toxic effects was noted between the two groups. CONCLUSIONS: The significant positive association observed between prescribed dose and survival suggests that individualized isotoxic dose-escalated radiation based on NTC might improve survival in this cohort of stage III NSCLC Chinese patients.
引用
- Zhao Q, Liu M, Wang Z, et al. High dose radiation therapy based on normal tissue constraints with concurrent chemotherapy achieves promising survival of patients with unresectable stage III non-small cell lung cancer. Radiother Oncol. 2019. PMID: 31869678. doi:10.1016/j.radonc.2019.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。